Genetic or pharmacological inhibition of plasmin effectively mitigated MAS-associated lethality and reduced cytokine peaks in animal models, indicating a critical role for plasmin in driving disease severity [168]. The gene discussed is PLG; the disease is macrophage activation syndrome.